Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules

Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients

Cipla EU to invest an additional € 3 million in Ethris

Cipla had earlier invested € 15 million in Ethris in 2022

USFDA completes audit of contract manufacturing facility of Jubilant Pharmova Montreal unit

The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations

Indian medical device industry to touch US$ 50 billion by 2030

India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary

Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,

Imfinzi approved in the US for endometrial cancer

Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy

Lupin and Fuji sign agreement for commercialization of Nextstellis in Vietnam and Philippines

Alembic announces USFDA final approval for Icatibant injection

This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals

Jubilant Pharmova announces voluntary prepayment of US$ 75 million term loan

As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore

Fischer Medical Ventures and The Therapy Platform partner for mental healthcare

Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions